Title:
THERAPEUTIC FOR HIGH-RISK MYELODYSPLASTIC SYNDROME
Document Type and Number:
WIPO Patent Application WO/2021/125261
Kind Code:
A1
Abstract:
The present invention pertains to a novel treatment method for myelodysplastic syndrome, the method being characterized by the combined use of azacitidine and thiopurine. Specifically, the present invention pertains to a drug for the treatment of myelodysplastic syndrome, the drug being characterized in that: azacitidine is subcutaneously or intravenously administered in a dose of 50-100 mg/m2 (body surface area) per day; and thiopurine is orally administered in the form of mercaptopurine hydrate in a dose equivalent to 0.5-2.0 mg/kg (body weight) per day, or is subcutaneously or intravenously administered in the form of mercaptopurine hydrate in a dose equivalent to 2-20 mg/m2 (body surface area) per day.
Inventors:
OGATA KIYOYUKI (JP)
YAMAMOTO YUMI (JP)
YAMAMOTO YUMI (JP)
Application Number:
PCT/JP2020/047149
Publication Date:
June 24, 2021
Filing Date:
December 17, 2020
Export Citation:
Assignee:
METROPOLITAN RES CENTER FOR BLOOD DISORDERS (JP)
International Classes:
A61K31/706; A61K9/08; A61K31/52; A61P35/02; A61P43/00
Other References:
HISAMATSU TADAKAZU: "6-Thiopurine/Azathioprine", THE JOURNAL OF PRACTICAL PHARMACY, vol. 67, no. 6, 2016, pages 2149 - 2153
PILORGE S. ET AL.: "The autommune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases", BRITISH JOURNAL OF HAEMATOLOGY, vol. 153, no. 5, June 2011 (2011-06-01), pages 664 - 665, XP055836224
WESNER N. ET AL.: "Inflammatory disorders associated with trisomy 8- myelodysplastic syndromes: French retrospective case-control study", EUR. J. HAEMATOL., vol. 102, no. 1, January 2019 (2019-01-01), pages 63 - 69, XP055836228
OSHIMI, KAZUO ET AL: "Chemotherapy and differentiation induction therapy in MDS", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 158, no. 11, 1991, pages 729 - 731
MIZOROGI F. ET AL.: "Oral administration of cytarabine ocfosfate and 6- mercaptopurine in elderly patients at high risk for myelodysplastic syndrome", JIKEIKAI MED. J., vol. 45, no. 3, 1998, pages 57 - 66
PILORGE S. ET AL.: "The autommune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases", BRITISH JOURNAL OF HAEMATOLOGY, vol. 153, no. 5, June 2011 (2011-06-01), pages 664 - 665, XP055836224
WESNER N. ET AL.: "Inflammatory disorders associated with trisomy 8- myelodysplastic syndromes: French retrospective case-control study", EUR. J. HAEMATOL., vol. 102, no. 1, January 2019 (2019-01-01), pages 63 - 69, XP055836228
OSHIMI, KAZUO ET AL: "Chemotherapy and differentiation induction therapy in MDS", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 158, no. 11, 1991, pages 729 - 731
MIZOROGI F. ET AL.: "Oral administration of cytarabine ocfosfate and 6- mercaptopurine in elderly patients at high risk for myelodysplastic syndrome", JIKEIKAI MED. J., vol. 45, no. 3, 1998, pages 57 - 66
Attorney, Agent or Firm:
OHNO Seiji et al. (JP)
Download PDF: